Assessment of the Effect of Once Daily Nitisinone Therapy on 24-h Urinary Metadrenalines and 5-Hydroxyindole Acetic Acid Excretion in Patients with Alkaptonuria After 4 Weeks of Treatment. by Davison, AS et al.
RESEARCH REPORT
Assessment of the Effect of Once Daily Nitisinone Therapy
on 24-h Urinary Metadrenalines and 5-Hydroxyindole
Acetic Acid Excretion in Patients with Alkaptonuria After
4 Weeks of Treatment
A. S. Davison • B. Norman • A. M. Milan •
A. T. Hughes • M. Khedr • J. Rovensky •
J. A. Gallagher • L. R. Ranganath
Received: 02 September 2017 /Revised: 23 October 2017 /Accepted: 27 October 2017
# Society for the Study of Inborn Errors of Metabolism (SSIEM) 2017
Abstract Background: One of the major metabolic con-
sequences of using nitisinone to treat patients with alka-
ptonuria is that circulating tyrosine concentrations increase.
As tyrosine is required for the biosynthesis of catecholamine
neurotransmitters, it is possible that their metabolism is
altered as a consequence. Herein we report the 24-h urinary
excretion of normetadrenaline (NMA), metadrenaline (MA),
3-methoxytyramine (3-MT) (catecholamine metabolites)
and 5-hydroxyindole acetic acid (5-HIAA, metabolite of
serotonin) in a cohort of AKU patients before and after a 4-
week treatment trial with nitisinone.
Materials and Methods: 24 h urinary excretions of NMA,
MA, 3-MT and 5-HIAA were determined by liquid chro-
matography tandem mass spectrometry. Interassay coeffi-
cient of variation was <10% for all analytes measured, at
all concentrations tested.
Results: Urine samples were assayed at baseline (pre-
nitisinone, n ¼ 36) and 4 weeks later; 7 received no
nitisinone (4 male, mean age (SD) 46.3 (16.4) years), and
29 received a daily dose of nitisinone [1 mg (n ¼ 7, 6 male,
mean age 45.9 (10.9) years), 2 mg (n ¼ 8, 5 male, mean
age 43.9 (13.7) years), 4 mg (n ¼ 8, 5 male, mean age 47.3
(10.7) years) and 8 mg (n ¼ 6, 4 male, mean age 53.8 (8.3)
years)]. 3-MT concentrations increase significantly
(p < 0.01, at all doses) following nitisinone therapy but
not in a dose-dependent manner. NMA concentrations
decreased (p < 0.05, at all doses) following nitisinone
therapy at all doses. 5-HIAA concentrations decreased
following nitisinone therapy and were significantly lower at
a daily dose of 8 mg only (p < 0.05).
Conclusions: This study shows that catecholamine and
serotonin metabolism is altered by treatment with nitisinone.
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Introduction
Alkaptonuria (AKU, OMIM: 203500) is a rare autosomal
recessive disorder of tyrosine metabolism (Fig. 1a) resulting
from a congenital lack in the enzyme homogentisate-1,2-
dioxygenase (HGD, E.C.1.12.11.5). It occurs in 1 in
250,000 of the general population (Phomphutkul et al.
2002); however in certain countries, it is observed more
commonly; for instance, in Slovakia it is estimated to occur
in 1 in 19,000 of the population (Zatkova 2011; Milch
1960). One of the major biochemical consequences of AKU
is that the circulating concentration of homogentisic acid
(HGA) significantly increases. HGA is central to the
pathophysiology of the disease and is thought to be
responsible for a number of abnormalities including
spondyloarthropathy, characterised by progressive kypho-
scoliosis and impaired spinal and thoracic mobility, as well
as renal and prostate stones, aortic valve stenosis, osteopo-
rosis, fractures and ruptures of tendons, ligaments and
muscle (Ranganath et al. 2013).
Supportive medical management of AKU includes a
low protein diet, analgesia and arthroplasty (Ranganath
et al. 2013). An additional HGA lowering therapy is
nitisinone (Fig. 1a), a competitive reversible inhibitor of
the enzyme hydroxyphenylpyruvic acid dioxygenase
(HPPD, E.C. 1.13.11.27). Its action reduces the accumula-
tion of HGA and thus has the potential to prevent or slow
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Fig. 1 (a) Tyrosine metabolic pathway – highlighting the site of the
enzyme defect observed in alkaptonuria and type 1 hereditary
tyrosinaemia and the site of action of nitisinone. (b) Catecholamine
metabolic pathway showing the formation of metadrenalines and (c)
tryptophan metabolic pathway – highlighting the proposed site
tyrosine inhibits tryptophan hydroxylase activity. TyH tyrosine
hydroxylase, AADC aromatic acid decarboxylase, COMT catechol-O-
methyl transferase, MAO monoamine oxidase, TrH tryptophan
hydroxylase
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the complications observed in patients with AKU. Cur-
rently nitisinone is not licenced for the treatment of patients
with AKU.
In contrast nitisinone is already licensed for the treat-
ment of hereditary tyrosinaemia type 1 (HT1) (HT I,
OMIM 276700) and has proved to be a very efficacious
mode of treatment (McKiernan 2013).
One of the major metabolic consequences of treating
patients with nitisinone in AKU and HT1 is that circulating
tyrosine concentrations increase significantly (Lindstedt
et al. 1992; Suwannarat et al. 2005; Introne et al. 2011;
Ranganath et al. 2016; Olsson et al. 2015; McKiernan et al.
2015; Milan et al. 2017). As tyrosine is the metabolic
substrate required for the biosynthesis of catecholamine
neurotransmitters (adrenaline (Ad), noradrenaline (NA) and
dopamine (DP)) (Fig. 1b), it is possible that they may be
altered during the 4-week treatment trial with nitisinone.
Hypertyrosinaemia is observed in patients with AKU
that attend the National AKU Centre in Liverpool (patients
are given 2 mg of nitisinone daily, off-licence) and during
the Suitability Of Nitisinone In Alkaptonuria 1 (SONIA-1)
clinical trial (Ranganath et al. 2016), which evaluated the
efficacy of different daily doses of nitisinone over a 4-week
period.
Significant elevations in serum and cerebral spinal fluid
tyrosine concentrations have also been a documented
consequence of nitisinone treatment in HT1 (Thimm
et al. 2011). In patients with HT1, it is believed that the
supraphysiological concentrations of tyrosine may be
responsible for the reduced intelligence quotient (IQ) and
cognitive function observed (Masurel-Paulet et al. 2008; De
Laet et al. 2011; Thimm et al. 2012; Bendadi et al. 2014;
Mckiernan et al. 2015).
The impact of hypertyrosinaemia on neurotransmitter
metabolism (Fig. 1b, c) in patients with AKU following
nitisinone therapy has not been previously reported. Herein
we report the 24-h urinary excretion of normetadrenaline
(NMA), metadrenaline (MA) and 3-methoxytyramine (3-
MT) (catecholamine metabolites) and 5-hydroxyindole
acetic acid (5-HIAA) (metabolite of serotonin) in patients
before and during the 4-week treatment trial with nitisi-
none.
Materials and Methods
Subjects
All urine samples were from subjects included in the
SONIA-1 clinical trial (trial registration number EudraCT
number: 2012-005340-24. Registered at ClinicalTrials.gov:
NCTO1828463). Twenty-four hour urine samples were
collected into 2.5 L bottles containing 30 mL of 5N
H2SO4; aliquots were stored away from bright light
at 80C. Urine samples analysed in this study were from
baseline (pre-nitisinone, n ¼ 36) and 4 weeks following no
treatment (n ¼ 7) or a daily dose of nitisinone [1 mg
(n ¼ 7), 2 mg (n ¼ 8), 4 mg (n ¼ 8) and 8 mg (n ¼ 6)]. No
patients included in this study had renal impairment
(eGFR > 60 mL/min/1.73 m2 in all cases). Completeness of
24-h urine collection was assessed by measurement of urine
creatinine (Roche Diagnostics, Germany); all patients had
urine creatinine concentrations within the normal reference
range (9.0–18.0 mmol/24 h, in-house reference range).
Analytical Methods
Urine Metadrenalines
The concentrations of urinary NMA, MA and 3-MT were
determined by liquid chromatography tandem mass spec-
trometry (Banks et al. 2014). 1 mL of urine underwent acid
hydrolysis (5M-HCl) at 100C for 30 min. 50 mL of
hydrolysate was diluted in 2 mL of deionised water
containing deuterated internal standards (D3-NMA,
0.11 mmol/L, D3-MA 0.10 mmol/L and D4-3-MT
0.12 mmol/L. CDN Isotopes, Essex) and loaded onto the
solid phase extraction plate (30 mg Evolute-SCX, Biotage,
Hengoed). 20 mL of extract was injected onto a C18 phenyl-
hexyl column (2.6 m, 4.6  100 mm, Phenomenex,
Cheshire) using a Waters Acquity UPLC separations
module coupled to a Xevo TQS tandem mass spectrometer.
Initial conditions of 90:10 water/methanol with 0.1%
formic acid (v/v) increased linearly to 40:60 over 2 min,
returning to starting conditions by 4 min. In-house calibra-
tion standards and commercial quality controls materials
(Recipe ClinChek, Germany) were used. Calibrator con-
centrations were 0–46.8 mmol/L for NMA, 0–24.8 mmol/L
for MA and 0–27.7 mmol/L for 3-MT. Interassay coef-
ficients of variation for NMA, MA and 3-MT were 4.6, 4.7
and 7.2% at 1.7, 0.8 and 1.6 mmol/L, respectively.
Urine 5-Hydroxyindole Acetic Acid
The concentration of urinary 5-HIAA was determined by
liquid chromatography tandem mass spectrometry. Samples
were diluted (20 mL urine in 2 mL) in deionised water
containing a deuterated internal standard (D5-5-hydroxyindole
acetic acid, 0.34 mmol/L, CDN Isotopes, Essex). 20 mL of the
diluted urine sample was injected onto an Atlantis dC18
column (2.6 m, 4.6  100 mm, Waters, Milford) using a
Waters Alliance 2795 separations module coupled to a Waters
Quattro Premier XE tandem mass spectrometer. Initial
conditions of 95:5 water/methanol with 0.1% formic acid
(v/v) and 2 mmol/L ammonium acetate increased linearly to
5:95 over 2 min, returning to starting conditions by 4 min.
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Fig. 2 Urinary metadrenaline concentrations in patients with alkaptonuria before treatment with nitisinone and after no treatment (n ¼ 7);
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Commercial calibration standards (3.6–356 mmol/L, Chrom-
systems, Germany) and quality controls materials (Recipe
ClinChek, Germany) were used. Interassay coefficient of
variation was 7.2% for 5-HIAA at 26.2 mmol/L.
Serum Tyrosine and Phenylalanine
The concentrations of serum tyrosine and phenylalanine
were determined by liquid chromatography tandem mass
spectrometry; for details see Hughes et al. (2015). Tyrosine
concentration was previously reported in the SONIA-1
clinical trial (Ranganath et al. 2016).
In this study data from only 36 of 40 subjects from
the SONIA-1 clinical were included. Serum tyrosine and
phenylalanine concentrations presented herein are from
subjects that had urine samples analysed for urinary
NMA, MA, 3-MT and 5-HIAA. All serum samples were
collected from patients after an overnight fast (at least 8 h).
Patients’ dietary intake of protein was not restricted during
this study, nor was it monitored.
Statistical Analysis
All statistical analysis was performed using GraphPad
Instat (version 3.10, 2009). Kolmogorov-Smirnov testing
was performed to assess if urinary NMA, MA, 3-MT and 5-
HIAA concentrations and serum tyrosine and phenylalanine
concentrations were normally distributed. Unpaired two-
tailed student t-test was used to assess significant differ-
ences in urinary metabolites pre- and post-treatment with
nitisinone; a p value <0.05 was deemed significant.
Results
Forty patients were included in the SONIA-1 study
(Ranganath et al. 2016). Urine samples from 36 of these
patients were available for inclusion in this study. Of the 36
patients, 7 patients received no treatment with nitisinone
(4 male, mean age (SD) 46.3 (16.4) years), and 29
patients received a daily dose of nitisinone [1 mg (n ¼ 7, 6
male, mean age 45.9 (10.9) years), 2 mg (n ¼ 8, 5 male,
mean age 43.9 (13.7) years), 4 mg (n ¼ 8, 5 male, mean
age 47.3 (10.7) years) and 8 mg (n ¼ 6, 4 male, mean age
53.8 (8.3) years)].
Urinary 3-MT concentrations increased significantly
(p  0.01, at all doses) following daily nitisinone therapy.
This occurred at all doses but not in a dose-dependent
manner. In contrast urinary NMA concentrations decreased
(p  0.03, at all doses) following nitisinone therapy.
Urinary MA concentrations were not significantly different
post-nitisinone therapy (Fig. 2).
Of interest a large proportion of patients had NMA
(reference range < 3.0 mmol/24 h), MA (reference range
< 1.3 mmol/24 h) and 3-MT (reference range < 1.4 mmol/
24 h) concentrations outside of the normal reference range
pre-nitisinone therapy. Following nitisinone therapy, NMA
concentrations were within the normal reference range in all
but one patient; however 3-MT concentrations were outside
of the reference range in all patients. MA concentrations
remained unchanged overall post-nitisinone therapy,
although there was less of a spread of concentrations
observed.
5-HIAA concentrations decreased following nitisinone
therapy (Fig. 3) and were significantly lower at a daily
dose of 8 mg (p < 0.05) only. 5-HIAA concentrations
were within the normal reference range (reference
range < 50 mmol/24 h) in the majority of patients pre-
(7/36 patients had elevated 5-HIAA) and post- (2/8 patients
receiving no nitisinone and 1/7 patients receiving 1 mg
nitisinone daily had elevated 5-HIAA) nitisinone therapy.
Fasting serum tyrosine concentrations increased signifi-
cantly following treatment with nitisinone at all doses
(p ¼ <0.0001). There were also significantly higher
tyrosine concentrations observed between subjects receiv-
ing 1 mg nitisinone versus 8 mg nitisinone (p ¼ <0.05) and
subjects receiving 2 mg nitisinone versus 8 mg nitisinone
(p ¼ <0.05), thus indicating a dose-dependent increase in
serum tyrosine concentrations following nitisinone. Mean (
standard deviation) concentrations were 59 (10) mmol/L
and 750 (140) mmol/L pre- and post-nitisinone therapy
(Fig. 4), respectively (reference range 30–87 mmol/L,
Davison et al. 2015).
Serum phenylalanine concentrations were not signifi-
cantly different following a 4-week trial of nitisinone
(p > 0.05 at all doses) and were within the normal reference
range (30–76 mmol/L, in-house reference range). Mean
(standard deviation) phenylalanine concentrations were
57.1 mmol/L (7.9) (pre-nitisinone, n ¼ 36), 55.7 mmol/L
(17.8) (no nitisinone, n ¼ 7), 53.0 mmol/L (6.0) (1 mg
⁄
Fig. 2 (continued) treatment with 1 mg nitisinone daily (n ¼ 7);
treatment with 2 mg nitisinone daily (n ¼ 8); treatment with 4 mg
nitisinone daily (n ¼ 8) and treatment with 8 mg nitisinone daily
(n ¼ 6). (a) 3-Methoxytyramine, (b) metadrenaline and (c) normeta-
drenaline. Dashed line ¼ indicates upper limit of normal urine
reference range for 3-methoxytyramine <1.4 mmol/24 h; metadrena-
line <1.3 mmol/24 h; normetadrenaline <3.0 mmol/24 h;  ¼ 95%
confidence notched outlier boxplot; + ¼ outlier; circle ¼ individual
patient concentrations. Significance testing compared metadrenaline
concentrations before and after a 4-week trial of nitisinone.
* ¼ p  0.01; ** ¼ p  0.03
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Fig. 3 Urinary 5-hydroxyindole acetic acid concentrations in patients
with alkaptonuria before treatment with nitisinone and after no
treatment (n ¼ 7); treatment with 1 mg nitisinone daily (n ¼ 7);
treatment with 2 mg nitisinone daily (n ¼ 8); treatment with 4 mg
nitisinone daily (n ¼ 8) and treatment with 8 mg nitisinone daily
(n ¼ 6). Dashed line ¼ indicates upper limit of normal urine reference
range for 5-hydroxyindole acetic acid, <50 mmol/24 h;  ¼ 95%
confidence notched outlier boxplot; + ¼ outlier; circle ¼ individual
patient concentrations. Significance testing compared 5-hydroxyindole
acetic acid concentrations before and after a 4-week trial of nitisinone.
*** ¼ p < 0.05
Fig. 4 Serum tyrosine concentrations in patients with alkaptonuria
before treatment with nitisinone and after no treatment (n ¼ 7);
treatment with 1 mg nitisinone daily (n ¼ 7); treatment with 2 mg
nitisinone daily (n ¼ 8); treatment with 4 mg nitisinone daily (n ¼ 8)
and treatment with 8 mg nitisinone daily (n ¼ 6). Dashed
line ¼ indicates normal serum reference range for tyrosine,
30–87 mmol/L;  ¼ 95% confidence notched outlier boxplot;
+ ¼ outlier; circle ¼ individual patient concentrations. Significance
testing compared tyrosine concentrations before and after a 4-week
trial of nitisinone and tyrosine concentrations in patients that received
different doses of nitisinone at 4 weeks of therapy (brackets compare
1 mg vs. 8 mg nitisinone and 2 mg vs. 8 mg nitisinone).
**** ¼ p < 0.0001; *** ¼ p < 0.05
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nitisinone, n ¼ 7), 51.6 mmol/L (13.0) (2 mg nitisinone,
n ¼ 8), 53.8 mmol/L (12.2) (4 mg nitisinone, n ¼ 8) and
53.8 mmol/L (13.4) (8 mg nitisinone, n ¼ 6).
Discussion
Significant hypertyrosinaemia following nitisinone therapy
has been previously reported in AKU (Suwannarat et al.
2005; Introne et al. 2011; Ranganath et al. 2016; Olsson et al.
2015; Milan et al. 2017). To date there are no reports on the
impact this may have on closely related metabolic pathways
that require tyrosine as a substrate, including the biosynthesis
of the catecholamine neurotransmitters (Fig. 1b).
Much of the literature focuses on hypertyrosinaemia
following nitisinone therapy in patients with HT1. It is
believed that the supraphysiological concentrations
observed may contribute to neurodevelopmental delay
(Masurel-Paulet et al. 2008; De Laet et al. 2011; Thimm
et al. 2012; Bendadi et al. 2014; Mckiernan et al. 2015). It
is estimated that up to 35% of children treated with
nitisinone have learning difficulties (McKiernan et al.
2015). It is not known whether this may also be related to
nitisinone treatment itself or low phenylalanine concen-
trations, presenting with acute liver disease or an intrinsic
effect of HT1.
Several mechanisms for neurodevelopmental delay have
been postulated. These include increased transport of
tyrosine into the brain, decreased transport of other neutral
amino acids into the brain (specifically tryptophan, the
precursor of serotonin), increased central nervous system
DP, decreased central nervous system serotonin, oxidative
damage from d-aminolevulinic acid and succinylacetone
modification of neuronal proteins (Thimm et al. 2011;
Harding et al. 2014; Hillgartner et al. 2016).
It has also been suggested that altered serotonin
metabolism may be due to direct inhibition of tryptophan
hydroxylase (TPH; EC 1.14.16.4) activity by tyrosine
(Fig. 1c), which leads to a reduced biosynthesis of
serotonin (Thimm et al. 2011). TPH is the rate-limiting
step in the biosynthesis of serotonin.
As it has been suggested that hypertyrosinaemia may
have an impact on neurodevelopmental delay in HT1,
concern exists around the use of nitisinone in AKU, which
is currently not licenced for treatment of this disorder.
While the dose prescribed to patients with AKU is much
lower than those with HT1 (2 mg daily at the National
Centre for AKU in Liverpool versus 0.5–2.5 mg/kg per day
in HT1), the concentration of serum and urine tyrosine
observed following nitisinone therapy is similar.
Herein for the first time, we report the impact of
nitisinone on the urinary excretion of the NMA, MA and
3-MT and 5-HIAA, which serve as surrogate markers for
catecholamine and serotonin neurotransmitter biosynthesis,
respectively (Fig. 1b, c). Urinary metabolites were
measured as collecting urine is non-invasive and is the
primary route for neurotransmitter elimination.
The marked increase in 3-MT and decreased NMA
excretion post-nitisinone therapy indicate that nitisinone
therapy alters the metabolism of catecholamines as the
concentration of their respective O-methylated metabolites
is altered when compared to pretreatment concentrations.
The metabolism of catecholamine neurotransmitters is
complex (Fig. 1b), and they have multiple origins (for
detailed overview, see Eisenhofer et al. (2004)), including
the sympathetic nerves, adrenal medulla, brain and
mesenteric organs (Eisenhofer et al. 2004). It has been
demonstrated that the concentration of monoamine neuro-
transmitters in urine is dependent on plasma concentration
and uptake via organic cation transporters (OCT) in the
kidney (Eisenhofer et al. 1996; Graefe et al. 1997).
However it is also essential to consider the degree to which
renal neurotransmitter synthesis can contribute to the
urinary concentrations. In the kidneys DP is produced via
the uptake and decarboxylation of circulating DOPA and
not just from the filtration of circulating DP (Eisenhofer
et al. 2004).
In this study 3-MT was shown to increase significantly
post-nitisinone therapy. 3-MT is a direct metabolite of DP
and thus may reflect increased circulating DP concentra-
tions and or synthesis in the kidney. It is proposed that the
latter is highly likely as the tyrosine load delivered to the
kidney increased significantly post-nitisinone therapy. This
was reported in the SONIA-1 dosing study (Ranganath
et al. 2016) and shown in the data presented herein where
mean serum tyrosine concentrations increased significantly
(p ¼ <0.0001) after a 4-week treatment with nitisinone
therapy (reference range 30–87 mmol/L, Davison et al.
2015). The increased tyrosine load delivered to the kidney
may provide a substrate for dihydroxyphenylalanine
(DOPA) synthesis, and thus the subsequent decarboxylation
of DOPA to DP may lead to the consequent increase in 3-
MT observed.
The elevated serum tyrosine concentrations observed
post-nitisinone therapy were accompanied by a significant
dose-dependent decrease in urinary excretion of HGA,
across the studied dose interval of 1–8 mg. The 8 mg dose
resulted in a mean reduction of 24-h urinary HGA excretion
of 98.8% compared with baseline (Ranganath et al. 2016).
Serum phenylalanine concentrations were not affected by
the marked increase in tyrosine following a 4-week trial
with nitisinone, indicating that tyrosine has an alternative
metabolic fate.
The impact of hypertyrosinaemia on serum tryptophan
concentrations was not evaluated in this short-term dose
evaluation study as it was not included in the original study
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design. However it has been shown at the National Centre
for AKU in Liverpool that serum tryptophan concentrations
do not change following a 2 mg daily dose of nitisinone
(unpublished, personal communication with Ranganath
L. R.). The authors postulate that serum tryptophan
concentrations will not be altered at a higher dose of
nitisinone as marked hypertyrosinaemia is observed at all
doses of nitisinone evaluated. Further work is required to
confirm this.
In this study tissue concentrations of tyrosine were not
determined to assess whether they correlate with serum and
urine concentrations. Further work into this area is required
to help understand the pathophysiology of AKU at a tissue
level.
Previously Thimm et al. (2011) reported tyrosine and
homovanillic acid (dopamine metabolite) concentrations in
the cerebral spinal fluid (CSF) of three patients with HT1
during long-term treatment with nitisinone. In this small
study, tyrosine concentrations were markedly increased in
the CSF and plasma, as expected. However homovanillic
acid concentrations were within the normal reference range,
suggesting that there is no alteration in dopamine metabo-
lism in the CNS. This supports the postulate that the
increased urinary 3-MT observed in this study is a
consequence of increased tyrosine load being delivered to
the kidney. It is also important to consider that dietary
constituents have been shown to influence urinary concen-
trations of 3-MT and thus represent one peripheral source of
dopamine metabolites (de Jong et al. 2009).
In this study dietary components rich in biogenic amines
were not restricted or documented. However as the data
presented herein show an increase in 3-MT in all patients
following a 4-week treatment with nitisinone, it is believed
that diet alone is not solely responsible for the increase in 3-
MT observed.
The parallel decrease in NMA suggests that there may be
a reduction in the synthesis of NA as a consequence of
nitisinone therapy. While there is limited information
available on the exact contribution of central and peripheral
output to urinary excretion of neurotransmitters, Graefe
et al. (1997) demonstrated that a significant proportion of
urinary NA and Ad stems from circulation. In this study
one may postulate that the observed decrease in NMA may
be a consequence of reduced sympathetic nerve excitation
as subjects are less depressed or anxious, as they are on
treatment for AKU. Previous studies (Hughes et al. 2004;
Roy et al. 1986a, b; Grossman and Potter 2009) have
evaluated the urinary concentration of NA and Ad in
subjects with depression, demonstrating that urinary con-
centrations of NA and Ad were significantly higher in
subjects with depression compared to controls. It is not
surprising that MA concentrations were not significantly
different post-nitisinone therapy as Ad is produced by the
adrenal gland and not the sympathetic nervous system,
mesenteric organs or kidney (Eisenhofer et al. 2004). The
reduced variability of MA concentrations observed follow-
ing a 4-week trial of nitisinone is of unknown significance
and is unlikely to reflect a change in diet; this requires
further investigation.
Another possibility is that there is an alteration in
inflammatory signalling following nitisinone therapy. Elen-
kov et al. (2000) demonstrated that Ad and NA can inhibit
the production of pro-inflammatory cytokines (i.e. interleu-
kin-2, tumour necrosis factor-a and interferon-g) and
stimulate the production of anti-inflammatory cytokines
(i.e. interleukin-10 and transforming growth factor-b). It
is postulated that altering these pathways may cause a
selective suppression of T helper-1 cells and cellular
immunity and enhancement of T helper-2 cell activity and
a shift towards humoral immunity.
While changes in urinary concentrations of NA, Ad and
their respective metabolites were not evaluated in this
study, one can postulate that they may be altered as a
consequence of changes in the inflammatory processes
observed following nitisinone therapy.
The decrease in 5-HIAA excretion at a daily dose of
8 mg only suggests that there is a dose-dependent effect of
nitisinone therapy. This supports that serotonin metabolism
is altered following treatment with nitisinone. Thimm et al.
(2011) also reported alterations in serotonin metabolism in
patients with HT1 treated with nitisinone. This study
showed a decrease in CSF 5-HIAA concentrations follow-
ing nitisinone therapy.
It is proposed that the decrease in CSF 5-HIAA occurred
as increased tyrosine concentrations compete with trypto-
phan (serotonin precursor) via a neutral amino acid
transporter across the blood–brain barrier, thus reducing
tryptophan availability for intracerebral serotonin synthesis
(Pratt 1982).
In addition it has been hypothesised that elevated
tyrosine may inhibit tryptophan hydroxylase (TPH; EC
1.14.16.4) activity (Fig. 2c), the rate-limiting step for
serotonin metabolism (Thimm et al. 2011). Although this
study was small and analysis was performed in CSF, it has
been shown that urinary analysis of serotonin and 5-HIAA
reflects parallel changes in immunoreactivity in the dorsal
raphe nucleus, demonstrating a positive correlation between
CNS serotonergic activity and urinary serotonin concen-
trations (Lynn-Bullock et al. 2004).
Conclusion
For the first time, alterations in neurotransmitter metabo-
lism have been reported in patients with AKU following
nitisinone therapy, specifically increased urinary 3-MT
JIMD Reports
(dopaminergic neurotransmitter metabolite), decreased
NMA (noradrenaline neurotransmitter metabolite) and
increased 5-HIAA (serotoninergic neurotransmitter metab-
olite) concentrations. The exact mechanism(s) causing these
changes are not known, and further work is required to
elucidate this and to establish whether these observations
truly reflect changes in CNS monoamine neurotransmitter
metabolism or contributions from peripheral or renal
metabolism.
Moreover it is recognised that these data are based on
a short-term dosing study, and it is necessary to assess
whether these changes would be observed in patients on
long-term therapy with nitisinone and to see if biochemical
changes correlate with changes in behaviour or mood.
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